ATE525400T1 - Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie - Google Patents

Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie

Info

Publication number
ATE525400T1
ATE525400T1 AT04028473T AT04028473T ATE525400T1 AT E525400 T1 ATE525400 T1 AT E525400T1 AT 04028473 T AT04028473 T AT 04028473T AT 04028473 T AT04028473 T AT 04028473T AT E525400 T1 ATE525400 T1 AT E525400T1
Authority
AT
Austria
Prior art keywords
antibodies
tumor cell
binding
allogenetic
gvhd
Prior art date
Application number
AT04028473T
Other languages
English (en)
Inventor
Horst Lindhofer
Shoshana Morecki
Shimon Slavin
Original Assignee
Trion Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trion Pharma Gmbh filed Critical Trion Pharma Gmbh
Application granted granted Critical
Publication of ATE525400T1 publication Critical patent/ATE525400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04028473T 2004-12-01 2004-12-01 Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie ATE525400T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04028473A EP1666500B1 (de) 2004-12-01 2004-12-01 Verwendung trifunktionaler Antikörper zur Risikoreduzierung von GvHD in einer allogenetischen anti-Tumor Zelltherapie

Publications (1)

Publication Number Publication Date
ATE525400T1 true ATE525400T1 (de) 2011-10-15

Family

ID=34927607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04028473T ATE525400T1 (de) 2004-12-01 2004-12-01 Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie

Country Status (2)

Country Link
EP (1) EP1666500B1 (de)
AT (1) ATE525400T1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2295080A3 (de) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-Zell-Verringerung mit CD37-spezifischen und CD20-spezifischen Bindungsmolekülen
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
ES2703780T3 (es) 2011-05-17 2019-03-12 Trion Res Gmbh Preparación de una vacuna que contiene anticuerpos trifuncionales con propiedades potenciadoras de la inmunogenicidad del antígeno
EP2524699A1 (de) * 2011-05-17 2012-11-21 Trion Research GmbH Impfstoffzubereitung mit trifunktionalen Antikörpern mit Antigenimmunogenität verbessernden Eigenschaften
CN106366189A (zh) * 2015-07-22 2017-02-01 中国医学科学院肿瘤医院 一种抗人肺癌干细胞的单克隆抗体
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
EP4165084A4 (de) 2020-06-14 2025-03-19 Shimon Slavin Multifunktionelle immunotherapeutische monoklonale antikörperkomplexe und konjugate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19725586C2 (de) * 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US7763243B2 (en) * 2001-08-17 2010-07-27 Roger Williams Medical Center In situ immunization

Also Published As

Publication number Publication date
EP1666500A1 (de) 2006-06-07
EP1666500B1 (de) 2011-09-21

Similar Documents

Publication Publication Date Title
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
IL311603B2 (en) Bispecific antibodies and compounds containing them for cancer treatment
CY1110874T1 (el) Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
TNSN05300A1 (en) Treatment with anti-vegf antibodies
CR9477A (es) Numero de copias del gen del receptor del factor de crecimiento epidermico
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
ATE538136T1 (de) Antikörper gegen connective tissue growth factor
EP2210939A4 (de) Anti-bst2-antikörper
EP2269656A3 (de) Ausgewählte antikörper und duramycin-peptide mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen und krebs
NO20062148L (no) Antistoffer som binder interleukin-4-reseptor
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
NO20064794L (no) Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon
EP2275445A3 (de) Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
WO2024173607A3 (en) Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
GB0102145D0 (en) Substances
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties